{
    "hands_on_practices": [
        {
            "introduction": "Evaluating a potential screening program is a cornerstone of preventive medicine in global health. The effectiveness of a test depends not only on its intrinsic accuracy, defined by sensitivity and specificity, but also on the prevalence of the disease in the population it is applied to. This exercise  demonstrates how to synthesize these factors to calculate two crucial metrics: the positive predictive value (PPV), which answers the critical question \"What is the chance I have the disease if I test positive?\", and the number needed to screen (NNS), which quantifies the overall effort required to prevent one adverse outcome.",
            "id": "4542326",
            "problem": "A country is evaluating a one-time, population-level screening test for a serious chronic disease as part of a national preventive medicine program. At the time of screening, the preclinical, screen-detectable prevalence is $1\\%$ (that is, $p = 0.01$ of the population is in the detectable, preclinical state). The test has sensitivity $90\\%$ and specificity $95\\%$. The treatable preclinical phase (TPCP) is $5$ years, during which early treatment is assumed to be effective. For clinically detected disease without screening, the $10$-year disease-specific case-fatality risk is $20\\%$. Early treatment following screen detection halves the $10$-year disease-specific mortality risk compared to usual care.\n\nAssume the following idealized conditions: all individuals accept screening and adhere to indicated follow-up and treatment; there is no overdiagnosis; all screen-detected cases are truly in the treatable preclinical phase and would have progressed to clinical detection within the treatable preclinical phase in the absence of screening; and competing risks and other-cause mortality do not affect the disease-specific $10$-year outcomes considered here.\n\nUsing only fundamental definitions of sensitivity, specificity, and conditional probability, and the definition of absolute risk reduction, compute:\n- the expected positive predictive value (PPV), defined as the probability of having preclinical, screen-detectable disease given a positive test; and\n- the number needed to screen (NNS) to avert one disease-specific death within $10$ years from screening.\n\nExpress the PPV as a decimal (not a percentage) and the NNS as a count of persons screened. Round both quantities to four significant figures.",
            "solution": "The user has provided a problem in preventive medicine that requires the calculation of two epidemiological metrics: the positive predictive value (PPV) and the number needed to screen (NNS).\n\n### Step 1: Extract Givens\nThe givens are as follows:\n-   Preclinical, screen-detectable prevalence: $p = 0.01$\n-   Test sensitivity: $90\\%$\n-   Test specificity: $95\\%$\n-   Treatable preclinical phase (TPCP): $5$ years (This is contextual information and, given the provided point prevalence, not required for the calculation).\n-   $10$-year disease-specific case-fatality risk for clinically detected disease (usual care): $20\\%$\n-   Efficacy of early treatment: halves the $10$-year disease-specific mortality risk.\n-   Idealized assumptions: perfect adherence, no overdiagnosis, all screen-detected cases would progress, and no competing risks.\n-   Required outputs: PPV (decimal, 4 significant figures) and NNS (count, 4 significant figures).\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded in the principles of epidemiology and screening. It uses standard definitions and metrics (prevalence, sensitivity, specificity, PPV, NNS, risk reduction). The given values are plausible for a real-world screening scenario. The problem is well-posed, providing all necessary information for a unique solution under the explicitly stated idealized assumptions. The language is objective and precise. The problem is not trivial and requires a multi-step application of fundamental concepts. Therefore, the problem is deemed valid.\n\n### Step 3: Formal Solution\n\nLet $D$ be the event that an individual has the preclinical, screen-detectable disease, and $D^c$ be the event that they do not. Let $T^+$ be the event of a positive test result and $T^-$ be the event of a negative test result.\n\nFrom the problem statement, we can define the following probabilities:\n-   The prevalence of the disease is $P(D) = 0.01$.\n-   The probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - 0.01 = 0.99$.\n-   The sensitivity of the test is the probability of a positive test given the disease is present: $P(T^+ | D) = 0.90$.\n-   The specificity of the test is the probability of a negative test given the disease is absent: $P(T^- | D^c) = 0.95$.\n-   From the specificity, we can derive the false positive rate, which is the probability of a positive test given the disease is absent: $P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - 0.95 = 0.05$.\n\n**Part 1: Calculation of the Positive Predictive Value (PPV)**\n\nThe PPV is the probability that an individual with a positive test result actually has the disease, defined as $P(D | T^+)$. We can compute this using Bayes' theorem:\n$$ \\text{PPV} = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)} $$\nThe denominator, $P(T^+)$, is the total probability of a positive test result in the population. It can be calculated using the law of total probability:\n$$ P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c) $$\nSubstituting the given values:\n$$ P(T^+) = (0.90)(0.01) + (0.05)(0.99) $$\n$$ P(T^+) = 0.009 + 0.0495 = 0.0585 $$\nNow, we can calculate the PPV:\n$$ \\text{PPV} = \\frac{0.009}{0.0585} = \\frac{90}{585} = \\frac{2}{13} \\approx 0.153846... $$\nRounding to four significant figures, the PPV is $0.1538$.\n\n**Part 2: Calculation of the Number Needed to Screen (NNS)**\n\nThe NNS to avert one adverse outcome (in this case, one disease-specific death within $10$ years) is the reciprocal of the absolute risk reduction (ARR) for the entire screened population.\n$$ \\text{NNS} = \\frac{1}{\\text{ARR}_{\\text{population}}} $$\nThe $ARR_{\\text{population}}$ is the total number of deaths averted per person screened. This can be calculated as the product of the probability of being a true positive case and the absolute risk reduction for an individual who is correctly identified and treated early.\n\nFirst, let's determine the probability that a randomly selected person from the population will be a true positive (i.e., has the disease AND tests positive). This is the joint probability $P(D \\cap T^+)$.\n$$ P(D \\cap T^+) = P(T^+ | D) P(D) = (0.90)(0.01) = 0.009 $$\nThis means that for every $1000$ people screened, we expect to find $9$ true cases of the disease.\n\nNext, we determine the absolute risk reduction for a single true positive case who receives early treatment.\n-   The $10$-year mortality risk with usual care (no screening) is $R_{\\text{usual}} = 0.20$.\n-   Early treatment halves this risk, so the $10$-year mortality risk with early treatment is $R_{\\text{early}} = \\frac{1}{2} \\times R_{\\text{usual}} = 0.5 \\times 0.20 = 0.10$.\n-   The absolute risk reduction for a treated individual is:\n$$ \\text{ARR}_{\\text{individual}} = R_{\\text{usual}} - R_{\\text{early}} = 0.20 - 0.10 = 0.10 $$\n\nNow, we can find the ARR for the total screened population. This is the risk reduction per individual screened, achieved by averting deaths only among the true positive cases.\n$$ \\text{ARR}_{\\text{population}} = P(D \\cap T^+) \\times \\text{ARR}_{\\text{individual}} $$\n$$ \\text{ARR}_{\\text{population}} = 0.009 \\times 0.10 = 0.0009 $$\nThis value signifies that screening one person reduces their absolute risk of dying from this specific disease within $10$ years by $0.0009$.\n\nFinally, we calculate the NNS:\n$$ \\text{NNS} = \\frac{1}{\\text{ARR}_{\\text{population}}} = \\frac{1}{0.0009} = \\frac{10000}{9} \\approx 1111.111... $$\nThe problem asks for the NNS as a count of persons, rounded to four significant figures. This gives an NNS of $1111$.\n\nTherefore, the calculated values are a PPV of $0.1538$ and an NNS of $1111$.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.1538 & 1111 \\end{pmatrix}}$$"
        },
        {
            "introduction": "A key task for any global health practitioner is to quantify the success of an intervention. Being able to estimate the impact of a program before it is even deployed is essential for planning, advocacy, and resource mobilization. This practice  provides a hands-on method for calculating one of the most intuitive measures of program achievement: the number of disease cases averted. By using baseline epidemiological data and an estimate of an intervention's effectiveness, you can translate public health action into a tangible and powerful result.",
            "id": "4542327",
            "problem": "A rural district plans to implement a household water chlorination program to reduce diarrheal disease. Prior routine surveillance estimated a baseline diarrheal incidence rate of $1.2$ episodes per person-year, assumed approximately constant over the next year and uniform across household members. The program is expected to produce a relative risk reduction of $0.3$ in diarrheal episodes, applied uniformly across all household members and sustained over the one-year observation period. Assume there are $1{,}000$ households in the district, with an average household size of $5$ persons, that all households adopt the program on January $1$, and that population size remains constant with negligible migration during the year. Using only the fundamental definitions of incidence rate and relative risk reduction, derive the expected number of diarrheal cases averted in these $1{,}000$ households over one year. Express your final answer as the number of cases averted. No rounding is required.",
            "solution": "The problem is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\n- Baseline diarrheal incidence rate ($IR_{baseline}$): $1.2$ episodes per person-year.\n- Relative risk reduction ($RRR$): $0.3$.\n- Number of households ($N_H$): $1,000$.\n- Average household size ($S_H$): $5$ persons.\n- Observation period ($T$): one year.\n- Assumption: The baseline incidence rate is constant and uniform.\n- Assumption: The relative risk reduction is uniform and sustained.\n- Assumption: All $1,000$ households adopt the program.\n- Assumption: Population size is constant with negligible migration.\n- Task: Derive the expected number of diarrheal cases averted over one year.\n- Constraint: Use only the fundamental definitions of incidence rate and relative risk reduction.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, well-posed, and objective. It is based on standard epidemiological principles and definitions (incidence rate, relative risk reduction, cases averted). The provided data are complete, consistent, and numerically plausible for a public health scenario. The simplifying assumptions (e.g., $100\\%$ adoption, constant population) are typical for introductory modeling problems to ensure a tractable and well-defined solution. The problem does not violate any of the criteria for invalidity.\n\n### Step 3: Verdict and Action\nThe problem is deemed valid. A formal solution will be derived.\n\n### Solution Derivation\n\nThe objective is to calculate the expected number of diarrheal cases averted ($C_{averted}$) over a period of one year. This quantity is defined as the difference between the number of cases expected without the intervention ($C_{baseline}$) and the number of cases expected with the intervention ($C_{intervention}$).\n\n$$C_{averted} = C_{baseline} - C_{intervention}$$\n\nFirst, we must determine the total population and the total person-time at risk. The total population ($P$) is the product of the number of households ($N_H$) and the average household size ($S_H$).\n$$P = N_H \\times S_H$$\nGiven $N_H = 1,000$ and $S_H = 5$, the total population is:\n$$P = 1,000 \\times 5 = 5,000 \\text{ persons}$$\n\nThe total person-time of observation ($PT$) is the product of the total population and the observation period ($T$).\n$$PT = P \\times T$$\nGiven $P = 5,000$ persons and $T = 1$ year, the person-time is:\n$$PT = 5,000 \\text{ persons} \\times 1 \\text{ year} = 5,000 \\text{ person-years}$$\n\nThe expected number of cases without the intervention, $C_{baseline}$, is calculated by multiplying the baseline incidence rate ($IR_{baseline}$) by the total person-time ($PT$).\n$$C_{baseline} = IR_{baseline} \\times PT$$\nUsing the given value $IR_{baseline} = 1.2$ episodes per person-year:\n$$C_{baseline} = 1.2 \\frac{\\text{episodes}}{\\text{person-year}} \\times 5,000 \\text{ person-years} = 6,000 \\text{ episodes}$$\n\nNext, we determine the incidence rate with the intervention ($IR_{intervention}$). The problem provides the relative risk reduction ($RRR$), which is defined in terms of the baseline and intervention incidence rates:\n$$RRR = \\frac{IR_{baseline} - IR_{intervention}}{IR_{baseline}}$$\nWe can rearrange this equation to solve for $IR_{intervention}$:\n$$IR_{intervention} = IR_{baseline} \\times (1 - RRR)$$\nSubstituting the given values $IR_{baseline} = 1.2$ and $RRR = 0.3$:\n$$IR_{intervention} = 1.2 \\times (1 - 0.3) = 1.2 \\times 0.7 = 0.84 \\frac{\\text{episodes}}{\\text{person-year}}$$\n\nThe expected number of cases with the intervention, $C_{intervention}$, is the product of the new incidence rate ($IR_{intervention}$) and the total person-time ($PT$).\n$$C_{intervention} = IR_{intervention} \\times PT$$\n$$C_{intervention} = 0.84 \\frac{\\text{episodes}}{\\text{person-year}} \\times 5,000 \\text{ person-years} = 4,200 \\text{ episodes}$$\n\nFinally, the number of cases averted is the difference between $C_{baseline}$ and $C_{intervention}$:\n$$C_{averted} = C_{baseline} - C_{intervention} = 6,000 - 4,200 = 1,800 \\text{ episodes}$$\n\nAlternatively, and more directly, the number of cases averted can be conceptualized as the total person-time multiplied by the absolute reduction in the incidence rate. The reduction in incidence rate ($\\Delta IR$) is $IR_{baseline} - IR_{intervention}$. From the definition of $RRR$, this reduction is equal to $IR_{baseline} \\times RRR$.\n$$\\Delta IR = IR_{baseline} \\times RRR$$\nTherefore, the number of cases averted is:\n$$C_{averted} = \\Delta IR \\times PT = (IR_{baseline} \\times RRR) \\times PT$$\nSubstituting the given values into this single expression:\n$$C_{averted} = (1.2 \\frac{\\text{episodes}}{\\text{person-year}} \\times 0.3) \\times 5,000 \\text{ person-years}$$\n$$C_{averted} = 0.36 \\frac{\\text{episodes}}{\\text{person-year}} \\times 5,000 \\text{ person-years}$$\n$$C_{averted} = 1,800$$\nThe expected number of diarrheal cases averted is $1,800$.",
            "answer": "$$\\boxed{1800}$$"
        },
        {
            "introduction": "In a world of finite resources, proving an intervention is effective is only the first step; we must also determine if it is cost-effective. Health economics provides a systematic framework for comparing different programs to ensure we generate the most health value from our investments. This exercise  introduces you to core tools of this field, including the incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB), using the standard outcome measure of Quality-Adjusted Life Years (QALYs). Mastering this analysis is crucial for making rational and equitable decisions in health policy and planning.",
            "id": "4542340",
            "problem": "A national health authority is comparing two alternative preventive care packages for chronic disease management in a high-income setting. Each package is characterized by an expected per-person cost and an expected per-person health outcome measured in Quality-Adjusted Life Years (QALYs). A Quality-Adjusted Life Year (QALY) is a measure of health benefit that adjusts life-years by health-related quality of life on a scale from $0$ (equivalent to death) to $1$ (perfect health). The decision-maker uses a willingness-to-pay threshold, denoted by $\\lambda$, interpreted as the maximum monetary amount the health system is willing to pay per additional QALY.\n\nThe two candidate interventions are:\n- Intervention A with expected cost $C_A = 100$ (in thousands of $2024$ United States dollars) and expected health $E_A = 2$ (QALYs).\n- Intervention B with expected cost $C_B = 160$ (in thousands of $2024$ United States dollars) and expected health $E_B = 3$ (QALYs).\n\nThe willingness-to-pay threshold is $\\lambda = 50$ (in thousands of $2024$ United States dollars per QALY).\n\nUsing only foundational definitions from cost-effectiveness analysis in preventive medicine and global health, compute the following:\n1. The incremental cost-effectiveness ratio of intervention B relative to intervention A, denoted $\\operatorname{ICER}_{B:A}$.\n2. The net monetary benefit (NMB) for each intervention at the given threshold $\\lambda$.\n\nAssume that the decision rule is to select the intervention with the larger expected net monetary benefit. Encode the preferred option as a numeric indicator $P$ where $P=0$ denotes intervention A is preferred and $P=1$ denotes intervention B is preferred.\n\nReport your final results in this order as a single row matrix:\n- $\\operatorname{ICER}_{B:A}$ in thousands of $2024$ United States dollars per QALY,\n- $\\operatorname{NMB}_A$ in thousands of $2024$ United States dollars,\n- $\\operatorname{NMB}_B$ in thousands of $2024$ United States dollars,\n- $P$ as defined above.\n\nRound your final numerical results to four significant figures and express them in the units specified above. If a value is exactly zero, write $0$.",
            "solution": "The problem will be validated by first extracting the given information and then assessing its scientific grounding, consistency, and clarity.\n\n### Step 1: Extract Givens\n- Intervention A:\n  - Expected cost: $C_A = 100$ (in thousands of $2024$ United States dollars).\n  - Expected health outcome: $E_A = 2$ (Quality-Adjusted Life Years, QALYs).\n- Intervention B:\n  - Expected cost: $C_B = 160$ (in thousands of $2024$ United States dollars).\n  - Expected health outcome: $E_B = 3$ (QALYs).\n- Willingness-to-pay threshold: $\\lambda = 50$ (in thousands of $2024$ United States dollars per QALY).\n- Objective 1: Compute the incremental cost-effectiveness ratio of B relative to A, $\\operatorname{ICER}_{B:A}$.\n- Objective 2: Compute the net monetary benefit (NMB) for each intervention.\n- Objective 3: Determine the preferred option, $P$, where $P=0$ if A is preferred and $P=1$ if B is preferred, based on the larger NMB.\n- Final Output Format: A single row matrix containing $[\\operatorname{ICER}_{B:A}, \\operatorname{NMB}_A, \\operatorname{NMB}_B, P]$, with numerical results rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem presented is a standard application of cost-effectiveness analysis, a core methodology in health economics, preventive medicine, and global health.\n\n- **Scientifically Grounded:** The concepts used—Quality-Adjusted Life Years (QALYs), willingness-to-pay threshold ($\\lambda$), incremental cost-effectiveness ratio (ICER), and net monetary benefit (NMB)—are foundational and well-established within the field. The problem is a textbook exercise in applying these definitions. It is scientifically sound.\n- **Well-Posed:** All necessary data ($C_A, E_A, C_B, E_B, \\lambda$) are provided. The objectives are clearly defined using standard formulas, and the decision rule is explicit. The comparison of intervention B to A is appropriate because B is both more costly ($C_B > C_A$) and more effective ($E_B > E_A$), placing it in the upper-right quadrant of the cost-effectiveness plane relative to A, which is the domain where ICER is the relevant decision metric. A unique, stable solution exists.\n- **Objective:** The problem is stated in precise, quantitative, and unbiased language. It is free of subjective or non-formalizable claims.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is a well-posed, scientifically grounded, and objective question that can be solved using the provided data and standard definitions from health economics. The solution process may proceed.\n\n### Solution Derivation\nThe problem requires the calculation of three quantities and one decision indicator.\n\n**1. Incremental Cost-Effectiveness Ratio ($\\operatorname{ICER}_{B:A}$)**\n\nThe ICER quantifies the additional cost per unit of additional health benefit gained when moving from one intervention (the comparator, A) to another (the proposed intervention, B). The formula is:\n$$ \\operatorname{ICER}_{B:A} = \\frac{\\Delta C}{\\Delta E} = \\frac{C_B - C_A}{E_B - E_A} $$\nSubstituting the given values:\n$C_A = 100$\n$E_A = 2$\n$C_B = 160$\n$E_B = 3$\n$$ \\operatorname{ICER}_{B:A} = \\frac{160 - 100}{3 - 2} = \\frac{60}{1} = 60 $$\nThe units are thousands of $2024$ USD per QALY. Rounding to four significant figures, the result is $60.00$.\n\n**2. Net Monetary Benefit (NMB)**\n\nThe NMB translates the health outcomes (QALYs) into monetary terms using the willingness-to-pay threshold ($\\lambda$) and subtracts the cost. It represents the net value of an intervention in monetary units. The formula for an intervention $i$ is:\n$$ \\operatorname{NMB}_i = (\\lambda \\times E_i) - C_i $$\nThe given willingness-to-pay threshold is $\\lambda = 50$.\n\n- **NMB for Intervention A ($\\operatorname{NMB}_A$)**:\n$$ \\operatorname{NMB}_A = (\\lambda \\times E_A) - C_A = (50 \\times 2) - 100 = 100 - 100 = 0 $$\nThe value is exactly $0$.\n\n- **NMB for Intervention B ($\\operatorname{NMB}_B$)**:\n$$ \\operatorname{NMB}_B = (\\lambda \\times E_B) - C_B = (50 \\times 3) - 160 = 150 - 160 = -10 $$\nThe value is $-10$. Rounding to four significant figures gives $-10.00$.\n\n**3. Preferred Option ($P$)**\n\nThe decision rule is to select the intervention with the larger NMB.\n- $\\operatorname{NMB}_A = 0$\n- $\\operatorname{NMB}_B = -10$\n\nComparing the two values, we find that $\\operatorname{NMB}_A > \\operatorname{NMB}_B$ since $0 > -10$. Therefore, intervention A is the preferred option. According to the problem definition, if intervention A is preferred, the indicator $P$ is set to $0$.\nSo, $P=0$.\n\nThis result is consistent with the comparison of the ICER to the willingness-to-pay threshold. Since $\\operatorname{ICER}_{B:A} = 60$ is greater than $\\lambda = 50$, the additional cost per QALY for choosing B over A exceeds the maximum amount the health system is willing to pay for an additional QALY. Thus, the more expensive intervention B is not considered cost-effective compared to A at this threshold, and A is preferred.\n\n**4. Final Answer Compilation**\nThe final results are compiled into a single row matrix in the specified order: $[\\operatorname{ICER}_{B:A}, \\operatorname{NMB}_A, \\operatorname{NMB}_B, P]$.\n- $\\operatorname{ICER}_{B:A} = 60.00$\n- $\\operatorname{NMB}_A = 0$\n- $\\operatorname{NMB}_B = -10.00$\n- $P = 0$\nThe resulting matrix is $[60.00, 0, -10.00, 0]$.",
            "answer": "$$ \\boxed{\\begin{pmatrix} 60.00 & 0 & -10.00 & 0 \\end{pmatrix}} $$"
        }
    ]
}